Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2017-05-05

FDA Approved: ADCIRCA — Supplemental Application (United Therapeutics Corporation)

View source ↗

Summary

The FDA highlights a supplemental application for ADCIRCA (tadalafil) submitted by United Therapeutics Corporation, likely related to labeling changes for its p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Adcirca (tadalafil)

Snippet

SUPPL AP for ADCIRCA (TADALAFIL)